PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31369645-3 2019 Here we examined sitravatinib (MGCD516), a spectrum-selective TKI able to block MET, TAM (TYRO3, AXL, MerTK) and multiple receptor families (including PDGFRs, VEGFRs, and Ephs). sitravatinib 17-29 MER proto-oncogene, tyrosine kinase Homo sapiens 102-107 34599023-1 2021 BACKGROUND: Sitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated macrophages ratio in the tumor microenvironment and have synergistic antitumor activity in combination with anti-programmed death-1/ligand-1 agents. sitravatinib 12-24 MER proto-oncogene, tyrosine kinase Homo sapiens 79-84 31369645-3 2019 Here we examined sitravatinib (MGCD516), a spectrum-selective TKI able to block MET, TAM (TYRO3, AXL, MerTK) and multiple receptor families (including PDGFRs, VEGFRs, and Ephs). sitravatinib 31-38 MER proto-oncogene, tyrosine kinase Homo sapiens 102-107 30385724-3 2018 Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MerTK) and split tyrosine-kinase domain-containing receptors (VEGFR and PDGFR families and KIT) plus RET and MET, targets that contribute to the immunosuppressive tumor microenvironment. sitravatinib 0-12 MER proto-oncogene, tyrosine kinase Homo sapiens 90-95